Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint
March 21, 2023 03:30 ET
|
Selecta Biosciences, Inc.; Sobi
--Response rate of 56% in patients treated monthly with high dose SEL-212 in DISSOLVE I and 47% in DISSOLVE II--In patients 50 years and older, response rate with high dose SEL-212 was 65% in DISSOLVE...
Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 02, 2023 07:30 ET
|
Selecta Biosciences, Inc.
- Topline data for Phase 3 DISSOLVE I & II clinical trials of SEL-212 in chronic refractory gout remains on track for Q1 2023 - - Continue to enroll patients in ReiMMAgine, the Phase 1/2 clinical...
Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Update
February 23, 2023 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference
February 07, 2023 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences Provides Business Update and Outlook for 2023
January 09, 2023 08:00 ET
|
Selecta Biosciences, Inc.
- Expected topline data for Phase 3 DISSOLVE I & II programs of SEL-212 in chronic refractory gout in Q1 2023 - - To receive $10 million upfront for the execution of a license agreement for Xork,...
Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection for IgA Nephropathy Program
December 14, 2022 08:00 ET
|
Selecta Biosciences, Inc.
– IgA protease candidate in combination with ImmTOR further enhances pipeline – – Novel mechanism of action of IgA protease has the potential to address the underlying kidney pathophysiology of IgA...
Selecta Biosciences Announces Appointment of Blaine Davis as Chief Financial Officer
November 28, 2022 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences to Participate at the Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day
November 07, 2022 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR®...
Selecta Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
November 03, 2022 08:00 ET
|
Selecta Biosciences, Inc.
– DISSOLVE I & II studies of SEL-212 in Chronic Refractory Gout remain on track for joint topline data readout in Q1 2023 – – SEL-302, Selecta’s wholly owned gene therapy in combination with...
Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Business Update
October 27, 2022 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR®...